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Abstract
Purpose Lung-RADS proposes malignancy probabilities for
categories 2 (<1%) and 4B (>15%). The purpose of this study
was to quantify and compare malignancy rates for Lung-
RADS 2 and 4B subsolid nodules (SSNs) on a nodule base.
Methods We identified all baseline SSNs eligible for Lung-
RADS 2 and 4B in the National Lung Screening Trial (NLST)
database. Solid cores and nodule locations were annotated
using in-house software. Malignant SSNs were identified by
an experienced radiologist using NLST information.
Malignancy rates and percentages of persistence were
calculated.
Results Of the Lung-RADS 2SSNs, 94.3% (1790/1897)
could be located on chest CTs. Likewise, 95.1% (331/348)
of part-solid nodules ≥6 mm in diameter could be located.
Of these, 120 had a solid core ≥8 mm, corresponding to cat-
egory 4B. Category 2 SSNs showed a malignancy rate of
2.5%, exceeding slightly the proposed rate of <1%.
Category 4B SSNs showed a malignancy rate of 23.9%. In
both categories one third of benign lesions were transient.
Conclusion Malignancy probabilities for Lung-RADS 2 and
4B generally match malignancy rates in SSNs. An option to
include also category 2 SSNs for upgrade to 4X designed for
suspicious nodules might be useful in the future. Integration of
short-term follow-up to confirm persistence would prevent
unnecessary invasive work-up in 4B SSNs.
Key points
• Malignancy probabilities for Lung-RADS 2/4B generally
match malignancy risks in SSNs.
• Transient rate between low-risk Lung-RADS 2 and high-risk
4B lesions were similar.
• Upgrade of highly suspicious Lung-RADS 2 SSNs to Lung-
RADS 4X might be useful.
• Up to one third of the benign high-risk Lung-RADS 4B le-
sions were transient.
• Short-term follow-up confirming persistence would avoid
unnecessary invasive work-up of 4B lesions.
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Abbreviations
SSN Subsolid nodule
NLST National Lung Screening Trial
Lung-RADS Lung Imaging Reporting and Data System
ACR American College of Radiology
CT Computer Tomography
PET Positron Emission Tomography
LDCT Low-dose CT
Introduction
Pulmonary subsolid nodules (SSNs) are a distinctive from
solid nodules with respect to CT morphology and underlying
pathology [1]. Among the group of SSNs, nonsolid (pure
ground-glass) nodules are differentiated from part-solid
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nodules dependent on the presence of a solid component. In
adenocarcinomas, the size of the solid component correlates
with the presence of an invasive component on pathology,
which has therapeutic and prognostic implications [2, 3].
Non-solid nodules are commonly associated with having a
more indolent behavior compared to part-solid nodules in
terms of doubling time and malignancy rate [4–7]. It is thus
not surprising that management recommendations make a dis-
tinction between part-solid and nonsolid nodules [1, 8, 9].
Similarly, as solid nodules, SSNs do not always present as
malignancies. SSNs are frequently caused by benign disease,
e.g. infection, focal fibrosis, and organizing pneumonia
[10–13]. Some guidelines therefore, recommend a 3-month
follow-up CT to check lesion persistence for nonsolid nodules
larger than 5 mm and part-solid nodules of all sizes [1, 14].
The Lung Imaging Reporting and Data System (Lung-
RADS™) was published in 2014 by the American College
of Radiology (ACR) to standardize interpretation of screen-
detected nodules and harmonize nodule management [8]. It
consists of numerous categories depending on nodule type
and diameter thresholds. Nodule management is adapted to
the relative risk of the nodule to represent or develop into a
malignancy. A summary of the Lung-RADS categories can be
found in Table 1.
Nonsolid nodules are in Lung-RADS category 2 if the di-
ameter is <20 mm. Nodules of that category are considered to
have a Bbenign appearance or behavior^ with a malignancy
probability of <1% [8]. Though known for their indolent be-
havior, studies have shown that nonsolid nodules may actually
represent invasive adenocarcinomas, especially when the le-
sion is larger than 10 mm [15, 16]. This makes Lung-RADS
category 2 susceptible to underestimation of the malignancy
risk. At the other end of the risk spectrum are category 4B
nodules, which represent the highest risk group with a malig-
nancy probability score >15%. They are characterized by a
solid core of ≥8 mm and management recommendations for
these lesions include a clinical chest CT, PET/CT, or a biopsy.
Opposed to other guidelines [1, 14], Lung-RADS does not
recommend a general 3-month low-dose follow-up for part-
solid nodules to confirm persistence. Only category 3 part-
solid nodules are recommended to have a 3-month follow-
up. This makes category 4B lesions susceptible to overestima-
tion of the malignancy risk because of the morphological
overlap with transient infectious nodules that might receive
unnecessary invasive diagnostics. Given the considerable
management consequences, we were interested to investigate
whether these two Lung-RADS categories reflect the proper
malignancy risk and consequently appropriate management
recommendations for SSNs.
For these reasons, we applied Lung-RADS categories 2
and 4B to SSNs of the largest publicly available database of
the National Lung Screening Trial (NLST). The purpose was
to quantify the actual malignancy rates on a nodule base and
compare these to the malignancy probabilities given by Lung-
RADS.
Materials and methods
Study group and nodule annotations
Chest CT scans from the NLST were used in this study [17].
All chest CT scans with at least one SSN annotated by the
NLST were analyzed, resulting in 3185 participants. The
NLSTwas approved by the institutional board at each partic-
ipating medical institution and participants provided written
informed consent before randomization [17]. CT data, demo-
graphics, and information on nodule classification, location,
and histology were made available from the NLST after ap-
proval of our project proposal.
We selected the type of the SSN according to the NLST
database. Longitudinal information about each SSNwas need-
ed, as well as which nodule resulted in lung cancer. However,
the NLST did not use unique lesion identifications for nodules
along the timeline, impeding determination of lesion persis-
tence. Likewise, no information about solid core size was
available in the NLST database. Thus, all eligible lesions were
reannotated by two medical students and a researcher with in-
house software that uses unique lesion identifications for each
nodule (CIRRUS Lung Screening, Diagnostic Image Analysis
Group, Nijmegen, the Netherlands). Lobe location, size, nod-
ule type, and section numbers stored in the NLST database
Table 1 Summary of Lung-RADS category 1 to 4X
Category Descriptor Category Malignancy probability Management recommendation
Negative 1 <1% Continue annual screening with LDCT in 12 months
Benign appearance or behavior 2 <1% Continue annual screening with LDCT in 12 months
Probably benign 3 1-2% 6-month LDCT
Suspicious 4A 5-15% 3-month LDCT; PET/CT may be used when there is a ≥ 8 mm solid component
4B >15% Chest CTwith/without contrast, PET/CT and/or tissue sampling depending
on the probability of malignancy and comorbidities. PET-CT may be
used when there is a ≥ 8 mm solid component
4X
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were used to annotate and characterize each positive nodule
(≥4 mm). Nodule classification as nonsolid or part-solid was
adopted from the NLST database. Lesion annotation was done
on baseline and follow-up CT scans. Lung-RADS categoriza-
tion was done for nodules on baseline scans and only this data
was subsequently analyzed. Information of follow-up scans
was used to determine persistence and growth of SSNs to
identify malignancies and infectious lesions.
Identification of malignancies on nodule base
NLST provides information on cancer diagnoses on par-
ticipant level, but no data are available on which nodu-
lar lesion indeed represented the actual malignancy.
Therefore, an experienced radiologist (ETS) identified
those nodules that were most likely to be the malignan-
cies. The procedure was aided by the anatomic informa-
tion from the NLST pathology database. Since only the
pulmonary lobe where the malignancy had been located
and the year of diagnosis were provided by the NLST
database, a scale from 0 to 4 was designed to code the
likelihood of correct malignancy identification:
0 = No lesion visible in the tumour lobe at baseline.
1 = Lesion highly unlikely to represent cancer.
2 = No decision possible.
(Lesion located in the tumour-bearing lobe that could po-
tentially develop into a malignancy over time, but diagnosis
was made >1 year apart of the last available screening CT and
available imaging did not reveal unequivocal signs of
malignancy.)
3 = Lesion highly likely to represent cancer.
(Lesion located in the tumour-bearing lobe and imaging
signs very suggestive for malignancy; however, diagnosis of
malignancy was made >1 year apart of the last available
screening CT.)
4 = Cancer.
(Lesion located in the tumour-bearing lobe on a screening
CT obtained in the year of tumour diagnosis and imaging
signs very suggestive for malignancy).
Imaging signs suggestive for malignancy included spicula-
tion of the solid component and/or evident growth on follow-
up.
Only lesions with scores 3 and 4 were included in the data
analysis. All SSNs not indicated as being diagnosed as malig-
nancies within the median 6.5 years of follow-up according to
the NLST database were considered benign.
Statistics
Malignancy rates, defined as number of malignancies divided
by the total number of lesions in this category multiplied by
100, were calculated for both categories 2 and 4B. Impact of
variable size thresholds were calculated for nonsolid nodules
in category 2. Percentages of transient and persistent lesions
were calculated for both Lung-RADS categories.
Results
Study population
The NLST database lists in total 1897 Lung-RADS 2
SSNs. This set consists of 1742 nonsolid nodules
<20 mm and 155 part-solid nodules <6 mm. Of these
nodules described in the NLST database, 94.4%
(1644/1742) of the nonsolid and 94.2% (146/155) of
the part-solid nodules could be securely located on the
CT images, and thus 1790 Lung-RADS 2 SSNs were
eligible for inclusion in this study. Reasons for lack of
identification were incomplete DICOM data (N=41) or
the fact that a lesion could not be found on the scan
(N=66).
Likewise, the NLST database lists 348 part-solid nodules
≥6 mm. Of these part-solid nodules ≥6 mm, 331/348 (95.1%)
could be located on the scans. Among this group, 120 lesions
had a solid core ≥8 mm, corresponding to Lung-RADS 4B.
Reasons for lack of identification were incomplete DICOM
data (N=7) or the lesion could not be found on the scan
(N=10).
Ten nodules (N=7 in Lung-RADS 2, N=3 in Lung-RADS
4B) had to be excluded in participants with score 0, 1, or 2
assigned during the malignancy identification process. Thus,
the final study group included in the statistical analysis
consisted of 1783 Lung-RADS 2 and 117 Lung-RADS 4B
nodules.
Malignant nodules in Lung-RADS category 2
Forty-four of the Lung-RADS 2 lesions (2.5%; 44/1783)
were found to be malignant (Table 2). The malignant
lesions had an average diameter of 9.9 mm. The vast
majority were nonsolid at baseline (N=42), the remain-
ing two were part-solid. At baseline 20 lesions were
<10 mm in diameter, 20 between 10 and 15 mm, and
4 between 15 and 20 mm. Eight lesions were resected
within 1 year of baseline, 13 in year 1 after baseline, 11
in year 2 after baseline, and 12 in year 3 after baseline
or later. Figure 1 shows examples of malignant category
2 lesions.
Of the benign Lung-RADS 2 lesions, 30.1% (523/1740)
were found to be transient. Thirty-four were part-solid and
489 were nonsolid. Of the transient nonsolid nodules at base-
line 391 were <10mm in diameter, 83 between 10 and 15mm,
15 between 15 and 20 mm.
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Impact of varying diameter thresholds on management
of Lung-RADS 2 nonsolid lesions
Lowering the threshold from 20 to 15 mm, would have
upgraded four of the 42 nonsolid malignancies to a
higher Lung-RADS category—and thus earlier follow-
up (6 months)—at the expense of earlier follow-up
scans for 49 benign nonsolid nodules. Accordingly, low-
ering the threshold from 20 to 10 mm, would have
correctly upgraded 24 malignant nodules to an earlier
follow-up but at the expense of earlier follow-up scans
for 262 benign nonsolid nodules.
Benign Nodules in Lung-RADS category 4B
In this subset of nodules, 28/117 (23.9%) lesions were found
to be malignant (Table 3). The remaining 89/117 (76.1%)
lesions were found to be benign. Malignant 4B lesions had
an average diameter of 18.0 mm. Eighteen lesions were
resected within one year of baseline, six in year 1 after base-
line, one in year 2 after baseline, and three in years 3 after
baseline or later. Twenty-seven out of the 89 (30.3%) benign
lesions were transient and were no longer present on the
follow-up screening CT scan. Six of the benign 89 nodules
had no follow-up scan to confirm or exclude persistence.
Figure 2 shows examples of transient and persistent category
4B lesions.
Discussion
In 2014, the ACR published Lung-RADS for screen-detected
pulmonary nodules. Similarly to other management recom-
mendations, it differentiates nodule types and uses nodule
diameter and growth as major input parameters [1, 8, 14,
18]. Nodule management is adapted to estimated malignancy
probability with category 2 corresponding to the finding of a
nodule with benign appearance and very low risk of being a
malignancy, and category 4B corresponding to the finding of a
suspicious nodule with a highmalignancy risk, requiring more
intense diagnostic work-up including biopsy or resection. In
Lung-RADS, thresholds for nodule diameters and corre-
sponding risk estimates had been determined by a consensus
panel of experts and were based on publications of data on a
summary-level of various screening trials including NLST,
ELCAP, and NELSON [19]. Recently, Pinsky et al. [19] pub-
lished a retrospective analysis of the Lung-RADS perfor-
mance in the NLST. Lung-RADS scores 1 and 2 were defined
as negative and scores 3 to 4B as positive screening results.
Fig. 1 Examples of malignant Lung-RADS category 2 subsolid nodules between 10–15 mm
Table 2 Malignancy rate of Lung-RADS category 2 subsolid nodules
Lung-RADS category 2 (N = 1783*)
Malignant 44 (2.5%)
Nonsolid 42
Part-solid 2
Benign 1739 (97.6%)
No follow-up scan 129 (7.4%)
nonsolid 122
part-solid 7
Transient 523 (30.1%)
nonsolid 489
part-solid 34
Persistent 1087 (62.5%)
nonsolid 984
part-solid 103
Within the category 2 group of benign lesions both transient and persis-
tent subsolid nodules can be found and are listed per nodule type.
Persistence could not be determined in lesions with no follow-up scan
available.
* excluding nodules with malignancy probability scores 0, 1, and 2 (N = 7
lesions)
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Performance was analyzed on participant level with respect to
the presence of diagnosed malignancy. However, no individ-
ual nodules were tracked and no differentiation was made
between part-solid nodules with various sizes of solid compo-
nents (categories 3-4A-4B), since this information is not au-
tomatically available by the NLST-database. The fact that a
subset of nonsolid nodules <20 mm in diameter is malignant
was well discussed, but no further information on distribution
of diameter with respect to histology was provided. We, there-
fore, focused our analysis on the two Lung-RADS categories
2 and 4B, the first with respect to the presence of malignancies
despite of low risk categorization, the latter because of its
potential overcall of transient infectious lesions as high-risk
nodules triggering substantial management consequences.
In our study, we found a malignancy rate of 2.5% in Lung-
RADS 2 subsolid lesions and 23.9% for Lung-RADS 4B
subsolid lesions. Malignancy-rates published by Lung-
RADS that include all nodule types are <1% for Lung-
RADS 2 and > 15% for Lung-RADS 4B.
Lung-RADS chose for a relatively large cut-off of 20 mm
for nonsolid nodules in the lowest risk category. Both the
Fleischner Society and, if there is no previous imaging, also
the British Thoracic Society, recommend an initial 3-month
follow-up for nonsolid lesions ≥5 mm to assess persistence.
The NCCN further differentiates between nodules <5 mm, 5–
10 mm, and larger and propose a generally closer follow-up
for nonsolid nodules: ≤5 mm yearly LDCT, and for lesions
>5-10 mm an LDCT in 6 months, and for lesions >10 mm an
LDCT in 3–6 months. Uniformly, all guidelines recommend
more invasive diagnostics in subsolid nodules with new or
growing (solid) components [1, 14, 20]. Pinsky et al. [19]
reported in their analysis of NLST data that Lung-RADS un-
derestimates the likelihood of lung cancer in subjects with
nonsolid lesions <20 mm or nodules <6 mm. In line with the
findings reported by Pinsky et al. [19] our analysis of NLST
nodules also showed a slight underestimation of the Lung-
RADS 2 probability score in subsolid nodules (2.5% versus
<1%).
A recent publication by I-ELCAP reported that nonsolid
nodules can be safely monitored with a 1-year follow-up scan
[21]. Similarly, Scholten et al. [22] found that long-term fol-
low-up appears to be safe to check for changes in SSNs. There
are, however, studies that have reported a non-negligible per-
centage of nonsolid lesions representing invasive carcinomas
[15; 16]. Hence, it is not yet clarified whether indeed all
nonsolid nodules represent indolent malignancies or whether
other texture features such as border characteristics or spatial
attenuation characteristics beyond diameter or lack of solid
component need to be considered to correctly assess malig-
nancy risk [23, 24]. Part of this controversy is most likely
related to the variability of differentiating nonsolid from
part-solid nodules [25, 26]. A general lowering of the thresh-
old to 15 or 10 mm seems not advisable given the disadvan-
tage of inducing large numbers of false-positive follow-ups
and the fact that I-ELCAP could not observe a stage shift/
deterioration of patient outcome applying a 1-year follow-up
strategy [21]. Interestingly 18% (8/44) of category 2 malig-
nancies were resected within 1 year of the screening CT, an-
other 55% (24/44) within the following 2 screening years,
supporting the idea that—although classified as category
2—they displayed some morphological features that made
Fig. 2 Examples of benign Lung-RADs 4B subsolid nodules, (a, b) persistent (c) transient
Table 3 Malignancy rate of Lung-RADS category 4B subsolid nodules
Lung-RADS category 4B (N = 117*)
Malignant 28 (23.9%)
Benign 89 (76.1%)
No follow up scan 6 (6.7%)
Transient 27 (30.3%)
Persistent 56 (62.9%)
Within the category 4B group of benign lesions both transient and per-
sistent subsolid nodules can be found. Persistence could not be deter-
mined in the lesions with no follow-up scan available.
* excluding nodules with malignancy probability scores 0, 1, and 2 (N = 3
lesions)
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them more suspicious. In addition to the size and nodule-type
based categories Lung-RADS includes an additional category
4X triggering more intense diagnostic work up. This category
is meant for categories 3, 4A, and 4B nodules that based on
visual assessment of the radiologist demonstrate suspicious ma-
lignant imaging features justifying an upgrade to a more intense
work-up. Currently, category 2 lesions are not included in such a
procedure. Therefore, instead of lowering diameter thresholds, it
could be an option to also allow for a subset of category 2 lesions
an upgrade to category 4X, when radiologists find suspicious
malignant imaging features. In that context it is noteworthy that
according to Pinsky et al. [19] proportion of stage 1 cancers and
5-year lung cancer-specific survival were not found to be signif-
icantly different between malignancies in Lung-RADS category
2 and malignancies in Lung-RADS categories 3, 4A, or 4B
subjects, indicating that category 2 malignancies cannot all be
considered as indolent [19]. Their results are thus at least partially
controversial to the findings published by Yankelevitz et al. [21].
It has to be noted that we do not know how many of the Lung-
RADS 2 subsolid lesions in our study group represented adeno-
carcinoma in situ (AIS) minimally invasive adenocarcinoma
(MIA) or indeed invasive adenocarcinomas. AIS and MIA have
a (near) 100% disease-free survival after resection and usually
grow slowly [27]. Several studies have investigated which mor-
phological features would allow for differentiating pre-invasive
from invasive nonsolid lesions [15, 28]. More research would be
beneficial to reveal more insight in predictive morphological
features of pre-invasive and invasive nonsolid nodules.
Quantification of the potential overestimation of category
4B SSNs was the other purpose of our study. This phenome-
non actually has a larger impact on patient management, since
category 4B results in a more intense and potentially invasive
work-up including a Bclinical chest CT, PET-CT, and/or tissue
sampling depending on the probability of malignancy, comor-
bidities, and the radiologist’s final decision^ [8].
Lung-RADS published an overall malignancy rate for all
nodule types of >15% for category 4B, which is in line with
the malignancy rate of 23.9% we found in our analysis for
SSNs. This indicates that from a statistical point-of-view there
is no overestimation. However, more importantly, one third
(30.3%) of the benign 4B SSNs were transient as confirmed
by follow-up. Although we conclude that the statistical malig-
nancy risk of Lung-RADS 4B SSNs is in agreement with the
Lung-RADS guidelines, our results represent a strong argu-
ment to include a short-term follow-up after three months to
confirm persistency before considering more invasive man-
agement strategies, as also has been suggested by other guide-
lines. The NCCN suggests to perform a LDCT in 3 months to
check for growthwhen there is low suspicion of lung cancer in
their highest risk group for part-solid nodules (>8 mm lesion
size). As for nonsolid nodules, the BTS recommends a 3-
month CT repeat in cases when there is no previous imaging
to assess persistence, growth, or change in morphology for
part-solid nodules as well. Similarly the Fleischner
Guidelines, designed for incidental nodule findings, recom-
mend always to do a short-term at 3 months to confirm per-
sistence in all part-solid nodules [1, 14, 20].
In both categories, we found that about one third of the lesions
were transient. This is an important finding because it eliminates
any need for further follow-ups. Previous studies report a wide
range of numbers for the rate of transient SSNs (ranging between
12-70%) [11, 21, 29–31]. Lee et al. [30] found a rather high rate
of 70% of 126 transient part-solid lesions seen in an Asian pop-
ulation. On the other hand, Yankelevitz et al. [21] who analyzed
screen-detected nonsolid nodules in a population comparable to
the NLST, reported results more similar to our findings. Their
study found that 26% (628/2392) of the nonsolid nodules seen at
baseline screening subsequently resolved or decreased. The
Multicentric Italian Lung Detection trial found similar results
with 31% (15/48) of nonsolid nodules to be transient but a lower
percentage of 12% (3/26) for part-solid nodules with a solid core
<5 mm [31]. Although our finding generally matches previous
literature, rate of persistence in SSNs appears to be influenced by
type and study group inclusion.
Our study has some limitations. First, the most important
limitation is the fact that SSNs not diagnosed as malignancies
within a median period of 6.5 years were considered benign
though no histological proof is available. However, this as-
sumption seems to be acceptable based on current data knowl-
edge and mirrored by the fact that current guidelines of the
Fleischner society recommend a maximum follow-up of SSNs
of 5 years [1]. Second, a small subset of SSNs could not be
localized as described in the methods section and were exclud-
ed. However, this concerned only a small percentage of nodules
and therefore it seems unlikely to have substantially influenced
results. The NLST does not provide any information which
nodule actually represented the resected malignancy. The stan-
dard of which nodule was considered malignant was deter-
mined by an experienced radiologist having anatomic informa-
tion and follow-up scans available. To exclude any indetermi-
nate or doubtful lesions a scoring system was defined and only
lesions with high confidence scores were included in the final
analysis. Third, pathologic subtypes were not available in the
NLST database at the time of analysis. Thus, further differenti-
ation between AIS, MIA and invasive adenocarcinomas was
not possible. Last, we used the nodule type classification of
the NLST-database, which is based on the assessment of the
local screening radiologist. Given the observer variability for
the assessment of presence and size of the solid core, it is likely
that a subset of SSNs might have been classified differently by
other observers [25, 26]. Taken together, the limitations might
have slightly influenced the percentages described, but are con-
sidered unlikely to have any impact on our conclusions.
In conclusion, malignancy probabilities for Lung-RADS 2
and 4B generally match the malignancy risks in SSNs. The
slight statistical underestimation of nonsolid nodules appears
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to be clinically less relevant given the generally indolent char-
acter of these lesions and the fact that the management differ-
ence only refers to the time interval of low-dose follow-up CT
scans. An option to include also category 2 SSNs for possible
upgrade to category 4X designed for more suspicious nodules
might be considered in the future; however, more research is
needed to define which imaging features qualify for such a
procedure. Our finding that one third of the benign 4B SSNs
were transient and thus falsely categorized as relatively high
risk nodules is of significant clinical importance. Integration
of a short-term low-dose follow-up to differentiate persistent
from transient lesions would avoid unnecessary invasive
work-up in Lung-RADS category 4B SSNs, and should,
therefore, be considered in future upgrades of Lung-RADS.
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